Page 1,523«..1020..1,5221,5231,5241,525..1,5301,540..»

Expanded diabetes center opens today – News – capecodtimes.com … – Cape Cod Times (subscription)

Posted: June 29, 2017 at 11:40 am

Cynthia McCormick @Cmccormickcct

WEST BARNSTABLE The YMCA Cape Cod is holding a grand opening of its newly renovated Weny Diabetes Resource Center at 5 p.m. today with an emphasis on nutrition counseling and classes for Cape Codders with diabetes and prediabetes.

Were trying to make this free and open to the public, said YMCA of Cape Cod CEO and President Stacie Peugh.

Individuals diagnosed with type 1 or 2 diabetes are entitled to five free visits with nutritionist Lauren Kunkler, Peugh said.

As part of its diabetes programming, the YMCA of Cape Cod also hosts prediabetes education and lifestyle coaching classes at the Mashpee-based Community Health Center of Cape Cod, Harbor Health Services in Hyannis, Duffy Health Center in Hyannis and the Falmouth Service Center, Peugh said.

The YMCA is planning to launch a support group for people with diabetes in collaboration with NAMI Cape Cod & the Islands, an advocacy group for people with mental illness, Peugh said.

There is actually a correlation between depression and diabetes, Peugh said during an interview in the newly renovated resource center, located by the front door of the YMCA.

With its blond wood shelving, soft blue-green walls and clear plastic furniture, the resource center is fairly small in size but was designed to appear bright and inviting, said Paula Drury of Brown, Lindquist Fenuccio & Raber Architects, the architect/designer for the project.

Located since 2008 at the back of the YMCA building where the front door used to be situated the new position is designed to attract the attention of the hundreds of people who enter the Y each day, Peugh said.

In addition to individual consulting, the diabetes center was designed to serve as a library and resource center for people with diabetes and their families, Drury said.

Websites relating to diabetes and health care have been built into two Apple desktop stations, and books and informational packets fill the resource centers book shelves.

The space and services offered are designed to help guide people past nutrition information overload and into useful, health-enhancing practices, Peugh said.

Diabetes is considered a metabolism disorder that affects the way the body uses food, according to information online from Cape Cod Healthcare.

The pancreas of diabetics either produces too little insulin, or the cells of the body do not respond to the insulin that is produced, according to the fact sheet.

The resulting glucose accumulation in the body can lead to multiple health issues including heart disease, kidney disease, stroke, nerve damage and blindness.

According to a public information platform called DataUSA, 8.6 percent of Barnstable County residents are living with diabetes. The percentage was based on data collected in 2013.

Todays open house will feature an appearance by Roger Ludwig, a trustee with the Weny Charitable Trust, and a discussion of the centers new partnership with NAMI, Peugh said.

Refreshments will be served. Peugh said the Weny Charitable Trust,which contributed $1 million to the expansion of the YMCA of Cape Cod 10 years ago, funded the relocation and renovation of the diabetes resource center with a gift of $100,000.

Follow Cynthia McCormick on Twitter: @CmccormickCCT.

Continued here:
Expanded diabetes center opens today - News - capecodtimes.com ... - Cape Cod Times (subscription)

Posted in Diabetes | Comments Off on Expanded diabetes center opens today – News – capecodtimes.com … – Cape Cod Times (subscription)

Diabetes management platform Glooko raises $35 million – TechCrunch

Posted: June 29, 2017 at 11:40 am

Glooko,a startup selling data management healthcare service on top of a device-agnostic platform to make it easier for doctors to remotely monitor patients,has pulled in $35 million Series C funding.It had previously raised $36 million in various rounds, bringing the total up to $71 million.

The startup was shy about how many were using the platform last time TechCrunch wrote about the company. But it was more forthcoming today, claiming to have helped more than 1 million patientsserved by 6,000+ providers so far.It will need to continue to rapidly expand to compete with some of the larger players in the space, like Dexcom and Medtronic.

Glooko plans to use the funding to help it get there by expanding itssales, marketing and development teams, as well asincreasing commercialization efforts in France, Germany, the U.K., Asia and the Middle East.

Toronto-based Georgian Partners led the round, along with other new investorsInsulet Corporation and Mayo Clinic. They join existing investors Canaan Partners, Social Capital, Medtronic and Samsung Next.

This additional funding will help us to further our mission: to improve the lives of people with diabetes, Glooko CEO Rick Altinger said. With this capital, we will accelerate our investments in clinical solutions that aim to increase medication adherence, provide personalized insights and prompts that drive behavior change for people with diabetes, and deliver clinical decision support to thousands of clinicians and coaches so they can better support people with diabetes in between office visits.

Read more:
Diabetes management platform Glooko raises $35 million - TechCrunch

Posted in Diabetes | Comments Off on Diabetes management platform Glooko raises $35 million – TechCrunch

If you really want to take control of your diabetes, follow these 4 tips – Star2.com

Posted: June 29, 2017 at 11:40 am

Lifestyle is a decisive factor in preventing or stabilising diabetes. From diet and exercise to stress management, here are a few lifestyle changes to consider.

Diabetics dont need to have to skip dessert, but they should definitely make wise food choices.

Pick products that have a naturally low glycemic index to prevent spikes in blood sugar.

Top fruits on that front are red berries (raspberries, strawberries, blackberries, blueberries), apples, pears, oranges, grapefruit, peaches and nectarines.

Note that cinnamon can help lower blood sugar levels.

It can be used to sweeten coffee or tea or sprinkled on yogurt or fromage frais.

Certain bakeries make cakes and cookies specifically for diabetics.

These sweet treats typically contain half the amount of sugar, notably by using natural sugar substitutes.

Still, they should only be eaten occasionally and always as part of a meal in order to limit the hyperglycemic effect.

Add berries and fruit to your deserts.

Most diabetics know that they should avoid pre-prepared supermarket dishes and ready meals.

These meals are often too high in fat and salt, and can be lacking in vitamins and minerals.

Cooking from scratch with quality produce remains the best option.

When it comes to grains, oats and barley are allowed.

These cereals fibres slow down the absorption of carbohydrates in the intestine and help control blood sugar levels and insulin requirements.

Walking for 10 minutes right after eating could be more effective for controlling blood sugar than walking at another time of day.

Do this after an evening meal, when blood sugar can drop by 22%, according to research from New Zealand.

Current recommendations from the World Health Organization (WHO) recommend at least the equivalent of 30 minutes of moderate-intensity physical activity per day, five times a week.

You can develop diabetes from too much stress and not enough sleep.

Unfortunately, it is possible to develop type-2 diabetes due to chronic stress from work or personal lives.

Permanent stress can contribute to increasing insulin resistance.

Thats why it is recommended to take regular exercise, learn relaxation techniques and organize break times on downtime in your day.

Keep an eye on shut-eye too (minimum seven hours sleep per night), as, according to several studies, this can help curb cravings for fatty or sugary foods, among other things. AFP Relaxnews

All comments are moderated. Your comment may not show up immediately. Please keep it clean and on topic. Offensive comments will not be published.

Continue reading here:
If you really want to take control of your diabetes, follow these 4 tips - Star2.com

Posted in Diabetes | Comments Off on If you really want to take control of your diabetes, follow these 4 tips – Star2.com

Scientists investigate link between air pollution and type 2 diabetes – Medical Xpress

Posted: June 29, 2017 at 11:40 am

June 29, 2017 Credit: CC0 Public Domain

An interdisciplinary team of scientists from the University of Leicester and other institutions has played a pivotal role in research investigating a possible link between air pollution and the rise in type 2 diabetes.

New research, published in the journal Environment International, examined data from 10,443 participants from diabetes screening studies in Leicestershire, UK.

The exposure to air pollution, the number of cases of type 2 diabetes and the impact of demographic and lifestyle factors were all considered.

The authors concluded that demographic factors largely explained the association between air pollution and type 2 diabetes.

The research team, supported by the NIHR, is comprised of University of Leicester experts from a wide variety of fields, including Earth Observation Science, the University's Diabetes Research Centre and the Department of Health Sciences and builds upon world-leading research in these areas.

Dr Gary O'Donovan, who led the research and is formerly of the University of Leicester and now at Loughborough University, said: "High air pollution and low physical activity are two of the leading causes of disease and premature death in middle and high-income countries.

"Like most cities in the UK, Leicester has only a handful of air quality monitors. The UN has estimated that two thirds of world's population will be living in cities by 2050 and our cities must become better, healthier places in which to live.

"Cities like Copenhagen in Denmark and Medelln in Colombia are doing a much better job of measuring air pollution and facilitating active transport than most cities in the UK."

Exposure to traffic related air pollutants is known to cause insulin resistance, a hallmark of the disease, and observational evidence has been applied to better understand a potential link.

Professor Roland Leigh, Technical Director of EarthSense and Director of Enterprise at the University of Leicester's Institute for Space and Earth Observation, and co-author of the study, said: "We know that air pollution is the world's largest environmental health risk affecting 92% of the population and associated with more than three million deaths per year, and evidence suggested it may contribute to the rise in type 2 diabetes.

"While original results suggested association between air pollution and associated particulates and type 2 diabetes, when the effects of lifestyle and demographic factors were considered, and given the limited size of the sample, evidence for direct association with air pollution was inconclusive.

"We will, however, continue to apply cutting-edge air quality research to unpick potentially connected long-term exposure factors," continued Professor Leigh. "As innovators in air quality monitoring, the University of Leicester and EarthSense has a fundamental contribution to make in the understanding of the complex issues of pollution exposure and health."

Diabetes is one of the leading causes of death in lower middle, upper middle and high income economies. The global prevalence of diabetes has nearly doubled, from 4.7% in 1980 to 8.5% in 2014, with the majority of cases being type 2. Experimental evidence exists to suggest exposure to nitrogen dioxide and associated particulate matter is related to inflammation and insulin resistance.

The CHAMPIONS Study into the association between air pollution and type 2 diabetes was conducted by representatives from the University of Leicester Diabetes Research Centre, University of Leicester Earth Observation Science Group, University of East Anglia Norwich Medical School and University of Leicester Department of Health Sciences.

EarthSense Systems is a joint venture between aerial mapping company Bluesky and the University of Leicester.

Explore further: New UK type 2 diabetes prevention programme shows 'promising' early results

More information: Gary O'Donovan et al, The association between air pollution and type 2 diabetes in a large cross-sectional study in Leicester: The CHAMPIONS Study, Environment International (2017). DOI: 10.1016/j.envint.2017.03.027

A programme aimed at preventing the development of Type 2 diabetes in people at high risk of the disease has achieved "promising" early results, a study has found.

People at high risk of developing type 2 diabetes can reduce their chances of getting the condition by more than 80 per cent by fully completing a new education programme, an NIHR-supported study has found.

Traffic noise, as well as air pollution, could affect heart health, according to new research.

Leading diabetes researchers believe smartphone craze Pokmon Go could be an "innovative solution" to rising obesity levels and chronic disease.

Exposure to air pollution at the place of residence increases the risk of developing insulin resistance as a pre-diabetic state of type 2 diabetes. Scientists of Helmholtz Zentrum Mnchen, in collaboration with colleagues ...

An interdisciplinary team of scientists from the University of Leicester and other institutions has played a pivotal role in research investigating a possible link between air pollution and the rise in type 2 diabetes.

A large, nationally representative survey in 2013 of adults in China finds that the estimated overall prevalence of diabetes was about 11 percent and that of prediabetes was nearly 36 percent, according to a study published ...

Some insulin is still produced in almost half of patients that have had type 1 diabetes for more than ten years. The study conducted by researchers at Uppsala University in Sweden has now been published online by the medical ...

Heart disease is a leading cause of death worldwide and exacerbated by type 2 diabetes, yet diabetes treatment regimens tend to focus primarily on blood sugar maintenance. This common approach to type 2 diabetes management ...

A team of researchers from Sweden, the U.S. and Switzerland has found that treating rat liver cells with a compound called sulforaphane, which is found in cruciferous vegetables, reduced production of glucose. In their paper ...

(HealthDay)For many people with diabetes, low blood sugar levels are a serious health risk, but researchers report that a new nasal powder quickly reverses the effects of this dangerous condition.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More:
Scientists investigate link between air pollution and type 2 diabetes - Medical Xpress

Posted in Diabetes | Comments Off on Scientists investigate link between air pollution and type 2 diabetes – Medical Xpress

Diabetes: J&J and Seventure Partners launch investment – European Biotechnology

Posted: June 28, 2017 at 10:42 pm

European venture capitalist Seventure Partners and Johnson & Johnson have invested US$12m in Israel-based DayTwo. Based on HbA1c, lifestyle factors and genetic analysis of the individual microbiome, the companys app analyses the individual microbiome to predict blood sugar responses to thousands of different foods.

Seventure Partners said it ran the investment through its Health for Life Capital investment vehicle, as part of a $12m series A fundraising.

DayTwo has exclusively licensed technology from Weizmann Institute to predict how a specific diet impacts the individual blood glucose level. After the companys app is fed with HbA1c results, lifestyle factors and sequence analyses of the individual microbiome, its machine-learning predictive algorithms provide personalised nutrition recommendations on a users smart device.

Seventure Partners announced its investment was made in syndication with Johnson & Johnson as well as historical investors. DayTwo wants to use the fresh capital to commercialise its product internationally beyond Israel and develop new products tailored for other user segments. According to DayTwo, currently, the app is marketed in Israel as a wellness product that targets highly-motivated consumers, giving them insight into how to manage the food choices that are best for them. The company is currently preparing the US market launch with the same purpose.

However, the companys ultimate goal is to additionally enter a higher-price market segment for its app: as a proven medical product that prevents or slows the development of diabetes. In February, DayTwo joined forces with J&J susidiary Janssen Biotech to develop personalised microbiome analysis for diabetes nutrition. The cooperation is designed to provide clinical data that will help DayTwo to submit the product for approval from the US Food and Drug Administration (FDA) and corresponding authorities in other countries.

According to Seventure Partners CEO Isabelle de Cremoux, DayTwo rounds out our microbiome portfolio. Current investments include French Enterome SA (microbiome modulator drugs, diagnostics and companion diagnostics), LNC (drug-probiotic and nutrition microbiome-modulator products), Maat Pharma (autologous microbiome transplant), TargEDys (bacteria for regulation of appetite) and Vedanta (drug-probiotic).

Read the original post:
Diabetes: J&J and Seventure Partners launch investment - European Biotechnology

Posted in Biotechnology | Comments Off on Diabetes: J&J and Seventure Partners launch investment – European Biotechnology

Karnataka IT and Biotechnology Dept Grants Rs 3.18 cr to 12 Start-ups – News18

Posted: June 28, 2017 at 10:42 pm

Bengaluru: The Karnataka IT and Biotechnology department on Wednesday granted Rs 3.18 crore to fund 12 start-ups in the areas of agriculture, biotechnology, security, communications and robotics.

"The dozen start-ups have been selected for funding to innovate products and solutions as they have been part of the Idea2PoC (Proof of Concept) scheme of the IT department's Start-up Cell," said an official statement in Bengaluru.

The Idea2PoC is a part of the country's first multi-sector start-up policy, unveiled by the state government to encourage entrepreneurs with funding to commercialise their innovation.

The start-ups with seed funding are Dr. Live Software (Rs 10 lakh), EasyKrishi (Rs 15 lakh), Lightmetrics (Rs 30 lakh), PiOctave Solutions (Rs 30 lakh), Geeksynergey Technologies (Rs 30 lakh), ispAgro Robotics (Rs 20 lakh), Astrome (Rs 30 lakh), Esyasoft (Rs 20 lakh), Geotraq Safety (Rs 45 lakh), NammaNimma Cycle Foundation (Rs 10 lakh), Sirena Technologies (Rs 48 lakh) and Selfdot Technologies (Rs 30 lakh).

"Though Bengaluru is the country's IT hub, we are seeing its start-up culture spreading to other areas, including agriculture, biotechnology, security, communications, robotics and gaming rapidly. Our aim is to mentor and help them to become self-sufficient," said IT & BT Principal Secretary Gaurav Gupta on the occasion.

Kartnataka Biotechnology and Information Techology Services (KBITS) Managing Director Salma K. Fahim said the state government was also targetting start-ups in emerging technologies such as animation, artificial intelligence, big data and virtual reality.

"These technologies can solve our long-standing problems, create hundreds of jobs and help in the 'Make in India' programme of the central and state governments," added Fahim.

See more here:
Karnataka IT and Biotechnology Dept Grants Rs 3.18 cr to 12 Start-ups - News18

Posted in Biotechnology | Comments Off on Karnataka IT and Biotechnology Dept Grants Rs 3.18 cr to 12 Start-ups – News18

ChineseInvestors.com, Inc.’s Wholly-owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Will Launch its First Hemp … – PR Newswire (press release)

Posted: June 28, 2017 at 10:42 pm

The new skin care line is expected to be launched in the third calendar quarter of 2017. CBD Biotechnology Co. Ltd. plans to use multiple sales channels to implement its sales plan including Tmall, TaoBao, the Company's official website, broadcasting platforms of internet celebrities, mobile news applications, and a multi-level direct selling system in cooperation with Shangdong Yibao Biologics Co. Ltd.

"Following the launch of OptHemp Ultra Premium Hemp Oil by CIIX's wholly owned U.S. subsidiary, ChineseHempOil.com, Inc., I am very pleased to announce the launch of CBD Biotechnology Co., Ltd. non-industrial hemp infused skin care line," says Summer Yun, CEO of CBD Biotechnology Co., Ltd. "CBD Biotechnology Co., Ltd. will be one of the first companies in China to incorporate hemp-based CBD into skin care products, which we believe will spark public interest.

"An estimated 55,700 metric tons of industrial hemp are produced around the world each year with China, Russia, and South Korea leading in production, accounting for 70 percent of the world's industrial hemp supply. Although China is one of the leading producers of industrial hemp, the benefits to the human body have not yet been widely recognized in mainland China," says Yun. "As one of the companies company to introduce a skin care line infused with hemp-based CBD to China, CIIX looks forward to educating the almost 1.4 billion people in China about the benefits of hemp-based CBD and the positive effects it can have on the largest, visible human organ - the skin!"

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds:https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Contact: ChineseInvestors.com, Inc. 227 W. Valley Blvd, #208 A San Gabriel, CA 91776

Investor Relations: Alan Klitenic +1-214-636-2548

Corporate Communications: NetworkNewsWire (NNW) New York, New York http://www.NetworkNewsWire.com +1-212-418-1217 Office Editor@NetworkNewsWire.com

SOURCE ChineseInvestors.com, Inc.

Go here to read the rest:
ChineseInvestors.com, Inc.'s Wholly-owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Will Launch its First Hemp ... - PR Newswire (press release)

Posted in Biotechnology | Comments Off on ChineseInvestors.com, Inc.’s Wholly-owned Foreign Enterprise, CBD Biotechnology Co. Ltd., Will Launch its First Hemp … – PR Newswire (press release)

Puma Biotechnology (PBYI) Lifted to Buy By Research Firm Zacks – Insider Tradings

Posted: June 28, 2017 at 10:42 pm

Research Firm Zacks boosted Puma Biotechnology (NYSE:PBYI) from a hold recommendation to a buy recommendation in a study note released on Early Thur, Jun 8th. Research Firm Zacks presently has $89.00 price objective on the biopharmaceutical firms shares.

Several stock researchers also recently released study analysis regarding the company. Citigroup boosted Puma Biotechnology to a buy recommendation and fixed a $105.00 price objective on the company shares in a study report on Sunday, May 28th. Stifel Nicolaus reissued a buy recommendation and gave a $105.00 target price on the stock of Puma Biotechnology in a study report on early Mon, Jun 5th. J P Morgan Chase & Co reaffirmed an overweight recommendation and given a $89.00 target price on the stock of Puma Biotechnology in a study report on early Tue, Jun 6th. Royal Bank Of Canada upped their target price on the stock of Puma Biotechnology from $60.00 to $88.00 and issued the shares a sector perform recommendation in a analysis report on Tue, Jun 6th. Lastly, Cowen and Company boosted Puma Biotechnology from a neutral recommendation to an outperform recommendation and fixed a $91.00 price objective on the company shares in a study analysis published on early Thur, May 25th. 1 equity analyst has recommended the share with a sell recommendation, two have published a hold recommendation and six have issued a buy recommendation to The corporation. the share presently has a consensus rating of Buy and an consensus price target of $86.94.

According to Research firm Zacks, Puma Biotechnology Stocks soared quite recently following an FDA advisory committee recommended approval of its lead pipeline candidate, neratinib for the treatment of HER2-positive breast cancers. As a development-stage company, Puma does not have any approved product in its portfolio yet. Thus, The corporation is totally dependent on its lead candidate neratinib for growth. With the latest FDA panel win, the approval of neratinib seems highly likely. An approval would be a huge rise for The corporation issued the immense commercial possible in the recipient market. However, dependence on the successful development and of a single candidate May severely hurt the firms growth prospects in case of any adverse development or regulatory setback. stocks of the company have outperformed the industry in the past 52 week.

Puma Biotechnology (PBYI) started trading at 85.95 on Early Thur. the firms valuation is $3.18 B. the company has 50 day SMA of $59.74 and a two hundred SMA of $42.39. Puma Biotechnology has a 52 week low of $27.64 and a 52 week high of $92.00.

Puma Biotechnology (NYSE:PBYI) previously issued its earnings report on early Wed, May 10th. The biopharmaceutical business posted ($1.97) EPS for the period, reaching the Zacks average forecast of ($2.06) by $0.09. on consensus, financial stock experts expect that Puma Biotechnology to post ($8.50) EPS for the present financial year.

In other Puma Biotechnology news, large stockholder Adage Capital Partners Gp, L.L unloaded 507,128 stocks of the firms shares in a trade dated Mon, Jun 5th. The stock was unloaded at a price range of of $87.84, amounting $44,546,123.52. The information was declared in a document with the securities and exchange commission, which is accessible through this link. executive have unloaded a total of 1,990,088 stocks of company shares valued $157,553,113 in the previous 90 days. corporate executives has an ownership of 22.70% of the firms stock.

Hedge funds have lately adjusted their holdings of The corporation. Bank of Montreal Can bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $195,000. Alambic Investment Management bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $201,000. Parametric Portfolio Associates bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $257,000. Perceptive Advisors bought a new stake in stocks of Puma Biotechnology in Q4 which is worth at $225,000. Lastly, Weiss Multi Strategy Advisers bought a new stake in stocks of Puma Biotechnology during the Q1 worth at $335,000. investment firms and many large funds has an ownership of 80.98% of the firms stock.

About Puma Biotechnology

Puma Biotechnology, is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The corporation focuses on in-licensing the development and commercialization rights to over around three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

The rest is here:
Puma Biotechnology (PBYI) Lifted to Buy By Research Firm Zacks - Insider Tradings

Posted in Biotechnology | Comments Off on Puma Biotechnology (PBYI) Lifted to Buy By Research Firm Zacks – Insider Tradings

iShares Nasdaq Biotechnology Index Fund (IBB) Rating Reduced by Vetr To Keep – Insider Tradings

Posted: June 28, 2017 at 10:42 pm

IShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) was lowered by investment analysts at crowd sourced stock rating company Vetr from a buy recommendation to a hold recommendation in a research note released to investors and clients on early Mon, Jun 5th. Firm has a $307.00 PT on the financial services providers shares. Vetrs target price points a possible drop of 1.25% from the firms prior close.

IShares Nasdaq Biotechnology Index Fund (IBB) transacted up 1.443% through out intraday market trading on early Mon, topping $315.375. 899,883 stocks of the shares transacted hands. Companys 50 Day SMA is $293.14 and its 200 SMA is $286.87. iShares Nasdaq Biotechnology Index Fund has a 1 year low of $240.30 has a 1 year high of $316.00.

On the other hand, Credit Suisse Group boosted iShares Nasdaq Biotechnology Index Fund from a market weight recommendation to an overweight recommendation in a study on Tue, Mar 21st. The move was based on the current stock valulation.

Most recently the business also announced a periodic dividend, expected to be paid on early Fri, Jun 30th. Investors with a record date on Early Thur, Jun 29th will be given a $0.1768 dividend. The ex-dividend date of this dividend is Tue, Jun 27th. this indicates a $0.71 dividend on a yearly basis and a payout of of 0.23%.

Quite a few investment firms and many large funds have acquired or sold some of the position in IBB. Morgan Stanley upped its stake in iShares Nasdaq Biotechnology Index Fund by 16.3% in the Q1. Morgan Stanley has an ownership of 1,774,505 stocks of the financial services providers shares valued $520,408,000 after scooping up an extra 248,914 shares through out the quarter. JPMorgan Chase boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 45.7% in the Q1. JPMorgan Chase has an ownership of 782,179 stocks of the financial services providers shares valued at $229,389,000 after scooping up an extra 245,458 shares through out the quarter. Alliancebernstein boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 40.9% in the Q1. Alliancebernstein has an ownership of 481,442 stocks of the financial services providers shares valued at $141,192,000 after scooping up an extra 139,657 shares through out the quarter. PNC Financial Services Group boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 1.0% in the Q1. PNC Financial Services Group has an ownership of 210,978 stocks of the financial services providers shares valued at $61,872,000 after scooping up an extra 2,112 shares through out the quarter. Lastly, Janney Capital Management boosted its position in stocks of iShares Nasdaq Biotechnology Index Fund by 34.6% in the Q1. Janney Capital Management has an ownership of 110,807 stocks of the financial services providers shares valued at $32,496,000 after scooping up an extra 28,503 shares through out the quarter. hedge fund investors and investment firms has an ownership of 69.06% of the firms stock.

About iShares Nasdaq Biotechnology Index Fund

IShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment data that correspond generally to the price and pay out performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Continued here:
iShares Nasdaq Biotechnology Index Fund (IBB) Rating Reduced by Vetr To Keep - Insider Tradings

Posted in Biotechnology | Comments Off on iShares Nasdaq Biotechnology Index Fund (IBB) Rating Reduced by Vetr To Keep – Insider Tradings

Mayo-Connected Regenerative Medicine Startup Inks Downtown Rochester Lease – Twin Cities Business Magazine

Posted: June 28, 2017 at 10:41 pm

A regenerative medicine startup led by a Mayo Clinic cardiologist is setting up shop in a downtown Rochesters Minnesota BioBusiness Center, according to newly filed city documents. The filing indicated Rion LLC, a Minnesota company registered to Dr. Atta Behfar of the Mayo Clinic Center for Regenerative Medicine, has signed a three-year lease for just over 2,000 square feet at the city-owned BioBusiness Center. The lease begins July 1. The nine-story BioBusiness Center opened in downtown Rochester in 2007 as a center for innovation in biotechnology, promoting the linkages between the researchers and practitioners at Mayo Clinic; instructors and students at the University of Minnesota Rochester, and the biotechnology business community. It houses the Mayo Clinic Business Accelerator among other tenants. Behfar is an assistant medical professor and leads a laboratory at Mayo concentrating on applying regenerative medicine the practice of using stem cells to regenerate damaged or missing tissue to prevent and cure chronic heart conditions. Specifically, his group focuses on development and use of both stem cells and protein-based therapies to reverse injury caused by lack of blood flow to the heart. The business direction of Rion, meanwhile, appears to be specifically geared toward a cutting-edge development in the field of regenerative medicine the use of extracellular vesicles (EVs) in speeding and directing the growth of regenerating tissues in the heart and elsewhere in the body. EVs, long brushed off by researchers as mere debris in the bloodstream, are membrane-enclosed spheres that break off from the surfaces of nearly all living cells when disturbed. They transport lipids, proteins and nucleic acids, and have now been found to be important players in cell-to-cell communication, influencing the behavior and even the identity of cells. Their emerging role in regenerative medicine could potentially be huge. For instance, by bioengineering them to transport protein payloads from stem cells, they can be used to signal the bodys own cells to regenerate tissue instead of transplanting the stem cells themselves, thus eliminating the chance of host immune system rejection. A patent application filed last year by Rion, Behfar, Mayo Center for Regenerative Medicine Director Dr. Andre Terzic and two other local inventors is aimed at adapting the healing properties of a specific type of EV into a unique kind of product that could have wide applications. It focuses on EVs derived from blood platelets, which are well known to stop bleeding, promote the growth of new tissues and blood vessels, relieve inflammation and provide a host of other benefits. The patent describes a system of encapsulating platelet EVs derived from human or animal blood into a platelet honey and delivering it to target areas of the body, such as damaged tissues or organs. Its purported effect is to regenerate, repair and restore damaged tissue, with possible uses including treating heart disease; healing damaged bones or joints; wound treatment; and cosmetic skin applications. A brief business description provided by Rion to Rochester city officials stated the company is focused on the delivery of cutting edge regenerative technologies to patients at low cost and in off-the-shelf fashion. Building on initial research at Mayo Clinic, Rion LLC aims to develop and bring to practice products in the space of wound healing, orthopedics and cardiac disease. The statement also added the company is an enthusiastic backer of Rochesters efforts to develop a local biotech business cluster, and is seeking to participate in the realization of the Destination Medical Center initiative.

See the article here:
Mayo-Connected Regenerative Medicine Startup Inks Downtown Rochester Lease - Twin Cities Business Magazine

Posted in Cell Medicine | Comments Off on Mayo-Connected Regenerative Medicine Startup Inks Downtown Rochester Lease – Twin Cities Business Magazine

Page 1,523«..1020..1,5221,5231,5241,525..1,5301,540..»